Goldman Sachs report: "Is curing patients a sustainable business model?"
by Cory Doctorow from on (#3MQSX)
In Goldman Sachs's April 10 report, "The Genome Revolution," its analysts ponder the rise of biotech companies who believe they will develop "one-shot" cures for chronic illnesses; in a moment of rare public frankness, the report's authors ask, "Is curing patients a sustainable business model?" (more")